Bank of New York Mellon
CERE

Bank of New York Mellon’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Bank of New York Mellon’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-249,362
Closed -$10.2M – 4197
2024
Q2 		$10.2M Sell
249,362
-40,282
-14% -$1.68M ﹤0.01% 1949
2024
Q1 		$12.2M Sell
289,644
-21,274
-7% -$894K ﹤0.01% 1859
2023
Q4 		$13.2M Buy
310,918
+47,228
+18% +$1.36M ﹤0.01% 1827
2023
Q3 		$5.76M Buy
263,690
+3,590
+1% +$89.8K ﹤0.01% 2238
2023
Q2 		$8.27M Buy
260,100
+24,402
+10% +$749K ﹤0.01% 2040
2023
Q1 		$5.75M Buy
235,698
+886
+0.4% +$26K ﹤0.01% 2225
2022
Q4 		$7.41M Buy
234,812
+8,407
+4% +$237K ﹤0.01% 2111
2022
Q3 		$6.4M Buy
226,405
+17,863
+9% +$532K ﹤0.01% 2158
2022
Q2 		$5.51M Sell
208,542
-198,621
-49% -$5.64M ﹤0.01% 2250
2022
Q1 		$14.3M Sell
407,163
-33,170
-8% -$969K ﹤0.01% 1877
2021
Q4 		$14.3M Buy
440,333
+17,172
+4% +$606K ﹤0.01% 1913
2021
Q3 		$12.5M Buy
423,161
+40,670
+11% +$1.14M ﹤0.01% 2002
2021
Q2 		$9.8M Sell
382,491
-448,297
-54% -$6.42M ﹤0.01% 2148
2021
Q1 		$11.4M Buy
830,788
+809,151
+3,740% +$11.8M ﹤0.01% 2018
2020
Q4 		$359K Buy
+21,637
New +$281K ﹤0.01% 3759

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Bank of New York Mellon's CERE Position: Q3 2024 in Review

Bank of New York Mellon sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 249,362 shares — an estimated $10.2M sold.

Bank of New York Mellon first reported a position in CERE in Q4 2020 and held it in 15 quarters. The position peaked at $14.3M in Q4 2021. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Bank of New York Mellon reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Bank of New York Mellon sold 249,362 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $10.2M.
  • Bank of New York Mellon first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2020 and held it in 15 quarters.
  • Bank of New York Mellon's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $14.3M in Q4 2021.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Bank of New York Mellon's 13F filing for Q3 2024, filed 12 Nov 2024.